(CRBN) Corbion - Overview
Exchange: AS •
Country: Netherlands •
Currency: EUR •
Type: Common Stock •
ISIN: NL0010583399
Stock: Lactic Acid, Food Ingredients, Bioplastics, Chemicals, Algae
Total Rating 41
Risk 90
Buy Signal -0.52
| Risk 5d forecast | |
|---|---|
| Volatility | 34.0% |
| Relative Tail Risk | -19.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.35 |
| Alpha | -18.12 |
| Character TTM | |
|---|---|
| Beta | 0.507 |
| Beta Downside | 0.273 |
| Drawdowns 3y | |
|---|---|
| Max DD | 47.10% |
| CAGR/Max DD | -0.28 |
Description: CRBN Corbion March 05, 2026
Corbion N.V. produces lactic acid, lactic acid derivatives, and other bio-based ingredients. The company operates in the specialty chemicals sector, which focuses on performance-enhancing products rather than commodity chemicals. Its business model involves developing and supplying ingredients for diverse applications such as food preservation, personal care, and pharmaceuticals.
Corbions product portfolio includes solutions for acidification, food safety, and shelf-life extension. It also offers biochemical specialties for various industrial uses and algae ingredients, which are increasingly used as sustainable alternatives in animal nutrition and supplements. The companys market reach extends across North America, Europe, Asia, and other regions.
The company serves multiple end markets, including food, home and personal care, animal nutrition, and bioplastics. Specialty chemical companies often differentiate themselves through research and development, offering customized solutions to meet specific client needs. Corbion distributes its products through a combination of direct sales and a distributor network. For further detailed analysis, consider exploring research on ValueRay.
Headlines to watch out for
- Lactic acid demand drives ingredient sales
- Algae ingredients expand sustainable product portfolio
- Food preservation solutions increase market share
- Raw material cost fluctuations impact profitability
- Regulatory changes affect bioplastics market
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 129.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 17.95 > 1.0 |
| NWC/Revenue: 10.70% < 20% (prev -0.39%; Δ 11.09% < -1%) |
| CFO/TA 0.24 > 3% & CFO 345.0m > Net Income 129.2m |
| Net Debt (436.4m) to EBITDA (379.9m): 1.15 < 3 |
| Current Ratio: 1.89 > 1.5 & < 3 |
| Outstanding Shares: last quarter (57.8m) vs 12m ago -3.15% < -2% |
| Gross Margin: 25.27% > 18% (prev 0.24%; Δ 2.50k% > 0.5%) |
| Asset Turnover: 164.0% > 50% (prev 130.3%; Δ 33.72% > 0%) |
| Interest Coverage Ratio: 4.63 > 6 (EBITDA TTM 379.9m / Interest Expense TTM 44.8m) |
Altman Z'' 4.91
| A: 0.19 (Total Current Assets 580.0m - Total Current Liabilities 306.6m) / Total Assets 1.42b |
| B: 0.50 (Retained Earnings 706.6m / Total Assets 1.42b) |
| C: 0.13 (EBIT TTM 207.3m / Avg Total Assets 1.56b) |
| D: 1.07 (Book Value of Equity 721.4m / Total Liabilities 674.3m) |
| Altman-Z'' Score: 4.91 = AAA |
Beneish M -3.46
| DSRI: 0.97 (Receivables 224.9m/200.9m, Revenue 2.56b/2.21b) |
| GMI: 0.93 (GM 25.27% / 23.54%) |
| AQI: 0.49 (AQ_t 0.09 / AQ_t-1 0.19) |
| SGI: 1.15 (Revenue 2.56b / 2.21b) |
| TATA: -0.15 (NI 129.2m - CFO 345.0m) / TA 1.42b) |
| Beneish M-Score: -3.46 (Cap -4..+1) = AA |
What is the price of CRBN shares?
As of March 24, 2026, the stock is trading at EUR 18.06 with a total of 219,836 shares traded.
Over the past week, the price has changed by -4.90%, over one month by -12.24%, over three months by -1.20% and over the past year by -7.49%.
Over the past week, the price has changed by -4.90%, over one month by -12.24%, over three months by -1.20% and over the past year by -7.49%.
Is CRBN a buy, sell or hold?
Corbion has no consensus analysts rating.
What are the forecasts/targets for the CRBN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 24.2 | 33.8% |
| Analysts Target Price | - | - |
CRBN Fundamental Data Overview March 20, 2026
Market Cap USD = 1.20b (1.04b EUR * 1.1562 EUR.USD)
P/E Trailing = 14.252
P/E Forward = 13.245
P/S = 0.822
P/B = 1.4579
P/EG = 1.2623
Revenue TTM = 2.56b EUR
EBIT TTM = 207.3m EUR
EBITDA TTM = 379.9m EUR
Long Term Debt = 313.1m EUR (from longTermDebt, last quarter)
Short Term Debt = 99.0m EUR (from shortTermDebt, last quarter)
Debt = 481.1m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 436.4m EUR (from netDebt column, last quarter)
Enterprise Value = 1.48b EUR (1.04b + Debt 481.1m - CCE 44.7m)
Interest Coverage Ratio = 4.63 (Ebit TTM 207.3m / Interest Expense TTM 44.8m)
EV/FCF = 7.67x (Enterprise Value 1.48b / FCF TTM 192.6m)
FCF Yield = 13.03% (FCF TTM 192.6m / Enterprise Value 1.48b)
FCF Margin = 7.54% (FCF TTM 192.6m / Revenue TTM 2.56b)
Net Margin = 5.06% (Net Income TTM 129.2m / Revenue TTM 2.56b)
Gross Margin = 25.27% ((Revenue TTM 2.56b - Cost of Revenue TTM 1.91b) / Revenue TTM)
Gross Margin QoQ = 24.96% (prev 27.14%)
Tobins Q-Ratio = 1.04 (Enterprise Value 1.48b / Total Assets 1.42b)
Interest Expense / Debt = 1.87% (Interest Expense 9.00m / Debt 481.1m)
Taxrate = 25.0% (10.8m / 43.2m)
NOPAT = 155.5m (EBIT 207.3m * (1 - 25.00%))
Current Ratio = 1.89 (Total Current Assets 580.0m / Total Current Liabilities 306.6m)
Debt / Equity = 0.65 (Debt 481.1m / totalStockholderEquity, last quarter 742.6m)
Debt / EBITDA = 1.15 (Net Debt 436.4m / EBITDA 379.9m)
Debt / FCF = 2.27 (Net Debt 436.4m / FCF TTM 192.6m)
Total Stockholder Equity = 749.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.29% (Net Income 129.2m / Total Assets 1.42b)
RoE = 17.23% (Net Income TTM 129.2m / Total Stockholder Equity 749.8m)
RoCE = 19.50% (EBIT 207.3m / Capital Employed (Equity 749.8m + L.T.Debt 313.1m))
RoIC = 13.13% (NOPAT 155.5m / Invested Capital 1.18b)
WACC = 5.76% (E(1.04b)/V(1.52b) * Re(7.77%) + D(481.1m)/V(1.52b) * Rd(1.87%) * (1-Tc(0.25)))
Discount Rate = 7.77% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -1.59%
[DCF] Terminal Value 80.82% ; FCFF base≈192.6m ; Y1≈126.5m ; Y5≈57.8m
[DCF] Fair Price = 24.31 (EV 1.84b - Net Debt 436.4m = Equity 1.40b / Shares 57.6m; r=6.0% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -34.60 | EPS CAGR: -45.43% | SUE: 0.0 | # QB: 0
Revenue Correlation: 66.45 | Revenue CAGR: 35.86% | SUE: -0.00 | # QB: 0
EPS current Year (2026-12-31): EPS=1.66 | Chg7d=-0.047 | Chg30d=+0.193 | Revisions Net=+0 | Growth EPS=+25.8% | Growth Revenue=+0.4%
EPS next Year (2027-12-31): EPS=1.80 | Chg7d=+0.000 | Chg30d=+0.150 | Revisions Net=+0 | Growth EPS=+8.8% | Growth Revenue=+3.8%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 0.9% (Discount Rate 7.9% - Earnings Yield 7.0%)
[Growth] Growth Spread = +2.9% (Analyst 3.8% - Implied 0.9%)
P/E Trailing = 14.252
P/E Forward = 13.245
P/S = 0.822
P/B = 1.4579
P/EG = 1.2623
Revenue TTM = 2.56b EUR
EBIT TTM = 207.3m EUR
EBITDA TTM = 379.9m EUR
Long Term Debt = 313.1m EUR (from longTermDebt, last quarter)
Short Term Debt = 99.0m EUR (from shortTermDebt, last quarter)
Debt = 481.1m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 436.4m EUR (from netDebt column, last quarter)
Enterprise Value = 1.48b EUR (1.04b + Debt 481.1m - CCE 44.7m)
Interest Coverage Ratio = 4.63 (Ebit TTM 207.3m / Interest Expense TTM 44.8m)
EV/FCF = 7.67x (Enterprise Value 1.48b / FCF TTM 192.6m)
FCF Yield = 13.03% (FCF TTM 192.6m / Enterprise Value 1.48b)
FCF Margin = 7.54% (FCF TTM 192.6m / Revenue TTM 2.56b)
Net Margin = 5.06% (Net Income TTM 129.2m / Revenue TTM 2.56b)
Gross Margin = 25.27% ((Revenue TTM 2.56b - Cost of Revenue TTM 1.91b) / Revenue TTM)
Gross Margin QoQ = 24.96% (prev 27.14%)
Tobins Q-Ratio = 1.04 (Enterprise Value 1.48b / Total Assets 1.42b)
Interest Expense / Debt = 1.87% (Interest Expense 9.00m / Debt 481.1m)
Taxrate = 25.0% (10.8m / 43.2m)
NOPAT = 155.5m (EBIT 207.3m * (1 - 25.00%))
Current Ratio = 1.89 (Total Current Assets 580.0m / Total Current Liabilities 306.6m)
Debt / Equity = 0.65 (Debt 481.1m / totalStockholderEquity, last quarter 742.6m)
Debt / EBITDA = 1.15 (Net Debt 436.4m / EBITDA 379.9m)
Debt / FCF = 2.27 (Net Debt 436.4m / FCF TTM 192.6m)
Total Stockholder Equity = 749.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.29% (Net Income 129.2m / Total Assets 1.42b)
RoE = 17.23% (Net Income TTM 129.2m / Total Stockholder Equity 749.8m)
RoCE = 19.50% (EBIT 207.3m / Capital Employed (Equity 749.8m + L.T.Debt 313.1m))
RoIC = 13.13% (NOPAT 155.5m / Invested Capital 1.18b)
WACC = 5.76% (E(1.04b)/V(1.52b) * Re(7.77%) + D(481.1m)/V(1.52b) * Rd(1.87%) * (1-Tc(0.25)))
Discount Rate = 7.77% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: -100.0 | Cagr: -1.59%
[DCF] Terminal Value 80.82% ; FCFF base≈192.6m ; Y1≈126.5m ; Y5≈57.8m
[DCF] Fair Price = 24.31 (EV 1.84b - Net Debt 436.4m = Equity 1.40b / Shares 57.6m; r=6.0% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -34.60 | EPS CAGR: -45.43% | SUE: 0.0 | # QB: 0
Revenue Correlation: 66.45 | Revenue CAGR: 35.86% | SUE: -0.00 | # QB: 0
EPS current Year (2026-12-31): EPS=1.66 | Chg7d=-0.047 | Chg30d=+0.193 | Revisions Net=+0 | Growth EPS=+25.8% | Growth Revenue=+0.4%
EPS next Year (2027-12-31): EPS=1.80 | Chg7d=+0.000 | Chg30d=+0.150 | Revisions Net=+0 | Growth EPS=+8.8% | Growth Revenue=+3.8%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 0.9% (Discount Rate 7.9% - Earnings Yield 7.0%)
[Growth] Growth Spread = +2.9% (Analyst 3.8% - Implied 0.9%)